Market Introduction

The global prediabetes market was valued at USD 280 million in 2023 and grew at a CAGR of 7% from 2024 to 2033. The market is expected to reach USD 550.80 million by 2033. The increasing prevalence of prediabetes in the global population will drive the growth of the global prediabetes market.

Prediabetes is the state in which blood glucose levels are too high to be considered normal, but not high enough to confirm diabetes. In most cases, it is a signal that a person is inclined/predisposed to get diabetes, heart ailments, and stokes. Prediabetes mostly arises when the body tissues are unable to respond adequately to the hormone insulin. For this reason, the pancreas will attempt to produce more insulin to try and get the same effect. Overtime it results in high blood sugars, though not as high as defined for diabetes, but significantly over normal range. Some people with prediabetes don’t have symptoms and may not even know they have the condition. However, its symptoms include obesity, high blood pressure or lack of exercise. It also affects those individuals of a certain ethnic origin. It is prevalent among the African, Hispanic, Native American and Asian origin individuals. Prediabetes is usually diagnosed through the blood tests including the fasting blood glucose test, oral glucose tolerance test and the haemoglobin A1c test, which give the amount of sugar in the blood after a given time. Pre-diabetes would, in most cases, be cleared up by changes in diet, exercise, and weight loss. For the people who fail to bring about modification to their lifestyle, prediabetes can lead to type 2 diabetes – a more severe and long-term disease. Thus, the early recognition and the subsequent treatment should be indispensable to stop the development of diabetes and to minimize the chances of developing complications associated with hyperglycaemia.

Get an overview of this study by requesting a free sample

Recent Development

• In order to determine who may develop eye issues and be at risk for future vision loss, a $3.3 million study at the University of Houston College of Optometry will monitor the health of individuals with diabetes and prediabetes. Wendy Harrison, an associate professor, is leading the study, which has funding from the National Eye Institute. 

Market Dynamics

Drivers

The increasing prevalence of prediabetes – The increasing rate of prediabetes and diabetes population drives the demand for prediabetes products and services. This coupled with unchanging trends in current global lifestyles that are less physically active and consume unhealthy diets is likely to contribute more to the increasing incidence of prediabetes and type 2 diabetes. The WHO report among other things estimates that millions of people are at a high risk of developing prediabetes. This, in turn, has kept the call for screening, blood glucose measurement, HbA1c or fasting blood glucose examinations on the rise. With the growth of a pre-diabetes population there is an increasing need and demand for early treatment, prevention and management that reduces the incidence of prediabetes and progression of the disease to type 2 diabetes. In addition to this, the rising knowledge level of health among people is another fundamental factor that is likely to boost the selling of prediabetes products. While governments, NGOs, and health organizations engage in campaigns that promote the importance of having access to quality health care, more people are knowing what comes with prediabetes and the need to go for tests. Due to encouragement towards healthy living leading to increased demand for gadgets such as glucose monitors, fitness trackers and nutrition guides, people are consuming products that help them with blood sugar management, right diet and more physical activity. Awareness creation through public health campaigns, and the words of advice by healthcare providers about preventive measures as well as methods to deal with the early stages of conditions, have also forced people to be active in their management of health, hence creating the market for prediabetes solutions.

Restraints

The lack of awareness and insufficient knowledge about prediabetes – A major factor that hinder growth of the prediabetes market is ignorance due to low health literacy levels. Most people are ignorant of the fact that they have prediabetes since the disease has no apparent symptoms. Also, the knowledge of prediabetes, its consequence, and the nature of developing into type 2 diabetes among the general population remains low. Although quite a number of awareness campaigns take place over preventive health, awareness creation still lags in reaching out to all populace specially in the rural or remote regions. Lack of knowledge about the disease and how to manage it means that people may not feel compelled to get diagnostic tests or blood glucose monitoring or to make life style changes that can prevent or cure prediabetes and therefore, the market for these product and services will remain limited.

Opportunities

Technological advancements and expanding digital health – Wearable devices and other assets like CGMs and mobile health apps give the possibility to monitor blood glucose levels, activity, and diet in real-time. All these technologies not only enable individuals to make the right decisions regarding their wellbeing, but also generate information useful to healthcare practitioners. For instance, CGMs are used to observe changes in glucose levels during the day, so the user can change their activity, diet, or medicine regimen. Also, there are mobile applications that connect to the Fitbit and remind people where they stand with their workout regime, and ensure they are consuming appropriate meals to avoid the development of Type 2 diabetes. Therefore, as these technologies become more easily available, they are likely to drive the market’s growth and development during the forecast period. Similarly, increasing costs of medical care have shifted both consumers and healthcare entities towards consistent prevention of diseases such as prediabetes. The economic costs associated with prediabetes has prompted governments, insurance companies and employers to shift their attention on early health screening, diagnosis and prevention.

Segment Analysis

Regional segmentation analysis

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America emerged as the most significant global prediabetes market, with a 40% market revenue share in 2023.

North America, and correspondingly the United States, is expected to cover the largest market share in the global prediabetes market owing to high incidence rates of prediabetes, well-developed healthcare system, and increased trend towards preventive care. Currently, the number of people with prediabetes and type 2 diabetes is significantly high in the U.S. given the rising obesity levels, established physically inactive lifestyles, and a growing population of the elderly. More than one in three U.S. adults have been diagnosed with prediabetes, putting an emphasis on screening, monitoring and management solutions. A large patient base has helped fuel the growth in prediabetes market because doctors and public health advocates are increasingly insisting on early diagnosis. North America continues to display the highest level of advanced health technology such as mHealth apps, wearables, and CGM. This technologically advanced environment pushes the need for novel healthcare solutions forward, which makes North America ideal for companies who deal in such products. Secondly, the fact that the region currently hosts pharmaceutical companies, and manufacturers of the medical device enhances accessibility of effective treatments.

Check the geographical analysis of this market by requesting a free sample

• Apple Inc. tried an app this year to help patients with prediabetes control their food intake and make lifestyle adjustments in an effort to gain more traction in the healthcare industry.  According to insiders who asked not to be named because the work is confidential, the business tested the service on a small number of employees earlier this year as part of its larger push into blood-sugar features. Apple may incorporate the technology into future health products, such as a noninvasive glucose tracker that it has been developing for over ten years, even if the company has no plans to sell the app just yet.

Diagnostic devices Segment Analysis

The diagnostic devices segment is divided into glucose monitors, haemoglobin A1c testing devices, oral glucose tolerance test kits, fasting blood glucose test kits, and lab diagnostics services. The glucose monitors segment dominated the market, with a market share of around 41% in 2023. Diagnostic products such as CGMs and blood glucose meters productively cover the diagnostic segment of the prediabetes market since they are widely used in diagnosing and monitoring of blood sugar level. Such gadgets enable person to track changes in their glucose levels and get data that is crucial for reversing or at best managing prediabetes. Especially CGMs which monitor blood glucose level 24/7 are more in demand because of their effectiveness and simplicity providing people with full information about glucose level changes and allowing them to adjust their lifestyle according to the data received. Furthermore, they are highly cost-effective, thereby increasing the accessibility for the general populace. Apart from that, other upgraded options like smartphone compatibility and compatibility with health applications also explain the growing usage of these gadgets, and therefore, they are considered as essential tools in the management of prediabetes.

Treatment and management solutions Segment Analysis

The treatment and management solutions segment are divided into lifestyle management programs, weight management programs, medication, and insulin sensitizers. The lifestyle management programs segment dominated the market, with a market share of around 47% in 2023. It has been found that if people achieved a 5–10% weight loss and did at least 150 minutes per week of moderate-intensity physical activity the risk of developing type 2 diabetes had been found to be reduced. Which is why lifestyle modification programs are advocated as the cornerstone in the management of prediabetes. Another advantage for why the development of lifestyle management programs has outgrown the disease management programs is the fact that people who follow such a plan get long-term solutions to their problems without having to take medications right away. Many of these programs can be designed based on the clients’ requirements: health objectives, and eating and exercising abilities. Additionally, most of the lifestyle management programs provide extended support in the form of counselling, group meetings, or application that serves as a reminder of the need to practice these changes continually. The need for such programs has been brought about by the rising trend of preventive healthcare services, and the recognition of the value of early treatment and detection of a specific illnesses. Also, they are in most cases cheaper than medication as well as other.

• Eli Lilly and Company revealed the comprehensive findings from the longest tirzepatide research to date, the Phase 3 SURMOUNT-1, which lasted three years and involved 176 weeks of therapy. When compared to a placebo, weekly tirzepatide (Zepbound and Mounjaro) injections (pooled 5 mg, 10 mg, and 15 mg dosages) significantly decreased the risk of type 2 diabetes progression in persons with pre-diabetes who were obese or overweight for a period of 176 weeks. For the efficacy estimandi, tirzepatide showed a sustained average weight reduction of 22.9% throughout the course of the three-year treatment period (15 mg dose). These results were just presented at ObesityWeek 2024 and published in The New England Journal of Medicine (NEJM).

Pharmaceuticals Segment Analysis

The pharmaceuticals segment is divided into oral medications, injectable medications, combination therapies, and over-the-counter supplements. The oral medications segment dominated the market, with a market share of around 39% in 2023. Currently, oral drugs especially Metformin’s accounts for the leading portion of the pharmaceutical segment of prediabetes due to its efficacy in controlling blood glucose and avoiding the development to T2D. Metformin, taken for prediabetes, is used most often because the drug increases insulin sensitivity and lessens the output of glucose by the liver. One pharmacological intervention which has been proved in clinical trials to reduce the incidence of T2DM and therefore serves as part of the cornerstone of intervention of prediabetes is oral antidiabetic agents. Metformin is particularly preferred for its efficacy, good tolerability, favourable side effect profile and long-term safety coupled with relatively low cost compared to recently developed oral antidiabetic drugs. The other importance feature that has led to the frequent use of Metformin and other oral medications is its accessibility. Oral medications are preferred by people diagnosed with prediabetes because they do not want injections or have strict dosing schedules. In doing so, it rises patient compliance and makes oral medications ideal for those who want a quick fix without much fuss.

Digital health solutions Segment Analysis

The digital health solutions segment is divided into mobile health apps, wearable devices, telemedicine services, and artificial intelligence (AI) and machine learning-based platforms. The mobile health apps segment dominated the market, with a market share of around 46% in 2023. Mobile health apps are the most deployed solutions in the prediabetes market because they are easily available, inexpensive, and flexible. These apps have become crucial to people with prediabetes since these offer holistic and customized solutions to people’s wellbeing. The most significant bonus to using mobile health apps is they offers the tracking of different health parameters in a single location, such as blood glucose levels, activity, food intake, and sleep. This integration in health data provides a complete picture in the condition of the user and prompt him on what lifestyle, input, diet and exercise to be taken which plays a vital role in managing prediabetes and avoiding type 2 diabetes. In addition, mobile health apps benefit from a higher level of reach since they can be installed on any device, meaning all classes of population have access to such apps, including the population from the developing countries and people with poor income. Furthermore, quite a number of mHealth apps are companions with other devices such as wearables, glucometers, and fitness trackers besides improving their performance and data interoperability. This integration has made it easier for the user to monitor his/her progress.

Some of the Key Market Players

• Abbott Laboratories
• Medtronic
• Novo Nordisk
• Dexcom
• Johnson & Johnson
• Sanofi
• Bayer AG
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb
• MannKind Corporation
• Eli Lilly and Company
• Glooko, Inc.
• Omron Healthcare

Report Description

• Market Introduction
• Market Dynamics
• Segment Analysis
• Some of the Key Market Players